← ANALYST RATINGS · TIPRANKS
Pyxis Oncology (PYXS): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy1 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $9.00, the highest $19.00, the lowest $6.00. The average is +435.7% from the last price of $1.68.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 → $2.00+33.3% | Hold | +19.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Hold | +19.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $6.00 | Buy | +257.1% | Reiterated | 08.10.26on TipRanks 21:45 | +1.4%next day −0.9% · 5 days −15.3% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $8.00 | Buy | +376.2% | Reiterated | 01.10.26on TipRanks 06:35 | −6.2%next day −3.0% · 5 days −10.4% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $6.00 → $8.00+33.3% | Buy | +376.2% | Reiterated | 26.09.26on TipRanks 10:30 | +2.1%next day +0.2% · 5 days −24.0% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $12.00 → $19.00+58.3% | Buy | +1,031.0% | Reiterated | 10.09.26on TipRanks Sep 9 11:10 | −12.6%next day −2.7% · 5 days −0.1% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Hold | — | Reiterated | 09.09.26on TipRanks 11:10 | −12.6%next day −2.7% · 5 days −0.1% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $7.00 | Buy | +316.7% | Reiterated | 17.08.26on TipRanks 22:06 | −0.3%next day +12.5% · 5 days +2.5% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $6.00 | Buy | +257.1% | Reiterated | 14.08.26on TipRanks 08:15 | +0.2%next day +0.8% · 5 days +3.7% | ↗ |
| Unknown Analyst | Guggenheim | $7.00 | Buy | +316.7% | Reiterated | 29.06.26on TipRanks Jun 30 15:45 | +1.6%next day +4.5% · 5 days +6.4% | ↗ |
| Sudan Loganathan★★★★★★★★★★#1955 · hits 65% · avg +22.0% | Stephens | $8.00 | Buy | +376.2% | Reiterated | 24.11.25on TipRanks 08:45 | +5.8%next day +2.7% · 5 days −26.0% | ↗ |
| Unknown Analyst | Jefferies | $7.40 | Buy | +340.5% | Reiterated | 13.11.25on TipRanks 10:40 | +4.2%next day −2.7% · 5 days +4.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Pyxis Oncology
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.00 at a price of $2.33 (+286.3%); now: $9.00 at $1.68 (+435.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 7 | 10 | 11 | 18 | 16 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.28 (from $-0.36 to $-0.22). Last quarter: $-0.40.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Pyxis Oncology
- CEO: Thomas Civik
- Employees: 56
- 321 Harrison Avenue, Boston, MA, 02118, US
- www.pyxisoncology.com
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 78 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗